The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“None of the patients in our study had detectable driver mutations in any follow-up samples using a Clinical Laboratory Improvement Amendments (CL1A)-certified 95-gene rapid heme panel with a variant allele fraction (VAF) sensitivity >1% (ref. 37).”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Research works printed but not linked: 26
- Cazzola, 2013, The genetic basis of myelodysplasia and its clinical relevance, Blood, 122, 4021, 10.1182/blood-2013-09-381665 · DOI
- Lindsley, 2013, The biology and clinical impact of genetic lesions in myeloid malignancies, Blood, 122, 3741, 10.1182/blood-2013-06-460295 · DOI
- Lundberg, 2014, Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, 123, 2220, 10.1182/blood-2013-11-537167 · DOI
- Matynia, 2015, Molecular genetic biomarkers in myeloid malignancies, Arch Pathol Lab Med, 139, 594, 10.5858/arpa.2014-0096-RA · DOI
- Meyer, 2014, Translational implications of somatic genomics in acute myeloid leukaemia, Lancet Oncol, 15, e382, 10.1016/S1470-2045(14)70008-7 · DOI
- Zoi, 2015, Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable, Int J Hematol, 101, 229, 10.1007/s12185-014-1670-3 · DOI
- Lindsley, 2015, Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, Blood, 125, 1367, 10.1182/blood-2014-11-610543 · DOI · Paper page
- Zhang, 2015, The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes, Leuk Res, 39, 6, 10.1016/j.leukres.2014.10.006 · DOI
- Kohlmann, 2014, Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing, Leuk Lymphoma, 55, 1725, 10.3109/10428194.2013.856427 · DOI
- Duncavage, 2012, Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia, Mod Pathol, 25, 795, 10.1038/modpathol.2012.29 · DOI
- Cheng, 2014, Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data, J Mol Diagn, 16, 504, 10.1016/j.jmoldx.2014.05.006 · DOI
- Luthra, 2014, Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring, Haematologica, 99, 465, 10.3324/haematol.2013.093765 · DOI
- Koskela, 2012, Somatic STAT3 mutations in large granular lymphocytic leukemia, N Engl J Med, 366, 1905, 10.1056/NEJMoa1114885 · DOI
- Treon, 2012, MYD88 L265P somatic mutation in Waldenström's macroglobulinemia, N Engl J Med, 367, 826, 10.1056/NEJMoa1200710 · DOI
- Weng, 2004, Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia, Science, 306, 269, 10.1126/science.1102160 · DOI
- Rossi, 2012, The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development, J Exp Med, 209, 1537, 10.1084/jem.20120904 · DOI
- Kon, 2013, Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms, Nat Genet, 45, 1232, 10.1038/ng.2731 · DOI
- Bonnet, 1997, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nat Med, 3, 730, 10.1038/nm0797-730 · DOI · Paper page
- Gambacorti-Passerini, 2015, Recurrent ETNK1 mutations in atypical chronic myeloid leukemia, Blood, 125, 499, 10.1182/blood-2014-06-579466 · DOI
- Thol, 2014, Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications, Blood, 123, 914, 10.1182/blood-2013-07-518746 · DOI
- Grasso, 2015, Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data, J Mol Diagn, 17, 53, 10.1016/j.jmoldx.2014.09.008 · DOI
- Hoogstraat, 2015, Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology, J Mol Diagn, 17, 10, 10.1016/j.jmoldx.2014.09.004 · DOI
- Kampa-Schittenhelm, 2013, Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms, Mol Cancer, 12, 19, 10.1186/1476-4598-12-19 · DOI
- Wang, 2013, Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation, Science, 340, 622, 10.1126/science.1234769 · DOI · Paper page
- Hatzimichael, 2013, Gene mutations and molecularly targeted therapies in acute myeloid leukemia, Am J Blood Res, 3, 29
- Kuo, 2015, Next-generation sequencing-based panel testing for myeloid neoplasms, Curr Hematol Malig Rep, 10, 104, 10.1007/s11899-015-0256-3 · DOI
Cited by
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
van Galen, P., Hovestadt, V., Wadsworth II, M. H., Hughes, T. K., Griffin, G. K., Battaglia, S., Verga, J. A., Stephansky, J., Pastika, T. J., Lombardi Story, J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.031 · Cited by 1,164
Self-citationHighly efficient therapeutic gene editing of human hematopoietic stem cells
Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., Baricordi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0401-y · Cited by 515
Van Egeren, D., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.02.001 · Cited by 206
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease
Spencer Chapman, M., Cull, A. H., Ciuculescu, M. F., Esrick, E. B., Mitchell, E., Jung, H., O’Neill, L., Roberts, K., Fabre, M. A., Williams, N., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02636-6 · Cited by 67
DeAngelo, D. J., Brunner, A. M., Werner, L., Avigan, D., Fathi, A. T., Sperling, A. S., Washington, A., Stroopinsky, D., Rosenblatt, J., McMasters, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.24968 · Cited by 16
Metadata
- Authors
- Kluk, M. J., Lindsley, R. C., Aster, J. C., Lindeman, N. I., Szeto, D., Hall, D., & Kuo, F. C.
- Venue
- The Journal of Molecular Diagnostics
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 18
- Issue
- 4
- Pages
- 507-515
- ISSN
- 1525-1578
- Cited by
- 178
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
